Innovative Treatment Project under the TÜBİTAK 2232-B International Young Researchers Program

Following her research at Charité University Hospital Berlin, Dr. Duygu Elif Yılmaz Demirci joined Yıldız Technical University and began conducting the project entitled “Suppression of Effective Molecular Pathways in Autosomal Dominant Polycystic Kidney Disease Using Nanoparticle-Based Drugs.” Supported under the TÜBİTAK 2232-B International Young Researchers Program, the project focuses on developing nanoparticle-based targeted drug delivery systems for genetic kidney diseases. By aiming to reduce side effects and improve treatment efficiency, the research contributes to the development of innovative therapeutic approaches in the field of precision medicine.